| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Nutritional Carcinogenesis [B.S.R., C. V. R.], American Health Foundation, Valhalla, New York 10595 and Searle Research and Development [K. S.], St. Louis, Missouri 63137
Epidemiological and laboratory studies indicate an inverse relationship between the risk of colon cancer development and intake of nonsteroidal antiinflammatory agents, including aspirin. One of the mechanisms by which nonsteroidal antiinflammatory agents inhibit colon carcinogenesis is through the inhibition of prostaglandin production by cyclooxygenase isozymes (COX-1 and COX-2). Overexpression of COX-2 has been observed in colon tumors. Thus, selective inhibitors of COX-2 could potentially serve as chemopreventive agents. We have assessed the chemopreventive properties of SC-58635, a COX-2 inhibitor, and of sulindac, as a positive control, in a double-blind study, using azoxymethane-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. Five-week-old male F344 rats were fed the control diet (modified AIN-76A) or experimental diets containing 150 or 1500 ppm SC-58635, 320 ppm sulindac, or 1500 ppm placebo. Two weeks later, all animals except those in vehicle (normal saline)-treated groups were s.c. injected with azoxymethane (15 mg/kg of body weight, once weekly for 2 weeks). At 16 weeks of age, all rats were sacrificed and colons were evaluated for ACF. As expected, dietary administration of sulindac suppressed ACF development as such and reduced crypt multiplicity in terms of number of aberrant crypts/focus. Administration of 1500 ppm SC-58635 inhibited total ACF induction and crypt multiplicity by about 40–49%. Our finding that SC-58635 significantly suppressed colonic ACF formation and crypt multiplicity strengthens the hypothesis that a selective COX-2 inhibitor possesses chemopreventive activity against colon carcinogenesis.
1 Supported in part by Searle Research and Development (St. Louis, MO).
2 To whom requests for reprints should be addressed, at the American Health Foundation, One Dana Road, Valhalla, NY 10595.
Received 7/19/96. Accepted 8/29/96.
This article has been cited by other articles:
|
|
 |
|
  M. Sahin, E. Sahin, and S. Gumuslu Cyclooxygenase-2 in Cancer and Angiogenesis Angiology, April 1, 2009; 60(2): 242 - 253. [Abstract] [PDF]
|
|
|
|
 |
|
 N. Wakimoto, I. Wolf, D. Yin, J. O'Kelly, T. Akagi, L. Abramovitz, K. L. Black, H.-H. Tai, and H. P. Koeffler Nonsteroidal Anti-inflammatory Drugs Suppress Glioma via 15-Hydroxyprostaglandin Dehydrogenase Cancer Res., September 1, 2008; 68(17): 6978 - 6986. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Iwase, T. Higuchi, T. Gonda, H. Kobayashi, H. Uetake, M. Enomoto, and K. Sugihara The Effect of Meloxicam, a Selective COX-2 Inhibitor, on the Microvasculature of Small Metastatic Liver Tumors in Rats Jpn. J. Clin. Oncol., September 1, 2007; 37(9): 673 - 678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. P. Spugnini, I. Cardillo, A. Verdina, S. Crispi, S. Saviozzi, R. Calogero, A. Nebbioso, L. Altucci, G. Cortese, R. Galati, et al. Piroxicam and Cisplatin in a mouse model of peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 6133 - 6143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, J. M.R. Patlolla, V. E. Steele, L. Kopelovich, B. S. Reddy, and C. V. Rao Chemoprevention of Familial Adenomatous Polyposis by Low Doses of Atorvastatin and Celecoxib Given Individually and in Combination to APCMin Mice. Cancer Res., July 15, 2006; 66(14): 7370 - 7377. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Zamuner, A. W. Bak, P. R. Devchand, and J. L. Wallace Predisposition to Colorectal Cancer in Rats with Resolved Colitis: Role of Cyclooxygenase-2-Derived Prostaglandin D2 Am. J. Pathol., November 1, 2005; 167(5): 1293 - 1300. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Moon, F. G. Bottone Jr., M. F. McEntee, and T. E. Eling Suppression of tumor cell invasion by cyclooxygenase inhibitors is mediated by thrombospondin-1 via the early growth response gene Egr-1 Mol. Cancer Ther., October 1, 2005; 4(10): 1551 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hughes-Fulford, R. R. Tjandrawinata, C.-F. Li, and S. Sayyah Arachidonic acid, an omega-6 fatty acid, induces cytoplasmic phospholipase A2 in prostate carcinoma cells Carcinogenesis, September 1, 2005; 26(9): 1520 - 1526. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Brown and R. N. DuBois COX-2: A Molecular Target for Colorectal Cancer Prevention J. Clin. Oncol., April 20, 2005; 23(12): 2840 - 2855. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Sangha, M Yao, and M M Wolfe Non-steroidal anti-inflammatory drugs and colorectal cancer prevention Postgrad. Med. J., April 1, 2005; 81(954): 223 - 227. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. T. Nam, K.-B. Hahm, S.-Y. Oh, M. Yeo, S.-U. Han, B. Ahn, Y.-B. Kim, J. S. Kang, D. D. Jang, K.-H. Yang, et al. The Selective Cyclooxygenase-2 Inhibitor Nimesulide Prevents Helicobacter pylori-Associated Gastric Cancer Development in a Mouse Model Clin. Cancer Res., December 1, 2004; 10(23): 8105 - 8113. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki, Y. Ito, K. Wakai, M. Kawado, S. Hashimoto, H. Toyoshima, M. Kojima, S. Tokudome, N. Hayakawa, Y. Watanabe, et al. Serum Oxidized Low-Density Lipoprotein Levels and Risk of Colorectal Cancer: A Case-Control Study Nested in the Japan Collaborative Cohort Study Cancer Epidemiol. Biomarkers Prev., November 1, 2004; 13(11): 1781 - 1787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Kelloff, R. L. Schilsky, D. S. Alberts, R. W. Day, K. Z. Guyton, H. L. Pearce, J. C. Peck, R. Phillips, and C. C. Sigman Colorectal Adenomas: A Prototype for the Use of Surrogate End Points in the Development of Cancer Prevention Drugs Clin. Cancer Res., June 1, 2004; 10(11): 3908 - 3918. [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, I. Cooma, J. M.R. Patlolla, B. Simi, B. S. Reddy, and C. V. Rao Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: Novel strategies for colon cancer prevention and treatment Mol. Cancer Ther., February 1, 2004; 3(2): 215 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-Y. Lee, Y.-A. Suh, J. W. Kosmeder, J. M. Pezzuto, W. K. Hong, and J. M. Kurie Deguelin-Induced Inhibition of Cyclooxygenase-2 Expression in Human Bronchial Epithelial Cells Clin. Cancer Res., February 1, 2004; 10(3): 1074 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sato, K. Yoshinaga, S. Okabe, T. Okawa, T. Higuchi, M. Enomoto, T. Takizawa, and K. Sugihara Cyclooxygenase-2 Expression and its Relationship with Proliferation of Colorectal Adenomas Jpn. J. Clin. Oncol., December 1, 2003; 33(12): 631 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Saha, K. R. Sekhar, C. Cao, J. D. Morrow, H. Choy, and M. L. Freeman The Antiangiogenic Agent SU5416 Down-Regulates Phorbol Ester-Mediated Induction of Cyclooxygenase 2 Expression by Inhibiting Nicotinamide Adenine Dinucleotide Phosphate Oxidase Activity Cancer Res., October 15, 2003; 63(20): 6920 - 6927. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. DiPerna, R. D. Bart, E. M. Sievers, Y. Ma, V. A. Starnes, and R. M. Bremner Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma J. Thorac. Cardiovasc. Surg., October 1, 2003; 126(4): 1129 - 1133. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. V. Swamy, C. R. Herzog, and C. V. Rao Inhibition of COX-2 in Colon Cancer Cell Lines by Celecoxib Increases the Nuclear Localization of Active p53 Cancer Res., September 1, 2003; 63(17): 5239 - 5242. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yamada and H. Mori Pre-cancerous lesions for colorectal cancers in rodents: a new concept Carcinogenesis, June 1, 2003; 24(6): 1015 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Chung, D. Wu, R. Gay, S. N. Han, B. Goldin, R. Bronson, J. Mason, D. E. Smith, and S. N. Meydani Effect of Age on Susceptibility to Azoxymethane-Induced Colonic Aberrant Crypt Foci Formation in C57BL/6JNIA Mice J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): B400 - 405. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Fischer, C. J. Conti, J. Viner, C.M. Aldaz, and R. A. Lubet Celecoxib and difluoromethylornithine in combination have strong therapeutic activity against UV-induced skin tumors in mice Carcinogenesis, May 1, 2003; 24(5): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Ermert, C. Dierkes, and M. Ermert Immunohistochemical Expression of Cyclooxygenase Isoenzymes and Downstream Enzymes in Human Lung Tumors Clin. Cancer Res., May 1, 2003; 9(5): 1604 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Miyata, S. Koga, S. Kanda, M. Nishikido, T. Hayashi, and H. Kanetake Expression of Cyclooxygenase-2 in Renal Cell Carcinoma: Correlation with Tumor Cell Proliferation, Apoptosis, Angiogenesis, Expression of Matrix Metalloproteinase-2, and Survival Clin. Cancer Res., May 1, 2003; 9(5): 1741 - 1749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. A. Minter, J. W. Eveson, S. Huntley, D. J. E. Elder, and A. Hague The Cyclooxygenase 2-selective Inhibitor NS398 Inhibits Proliferation of Oral Carcinoma Cell Lines by Mechanisms Dependent and Independent of Reduced Prostaglandin E2 Synthesis Clin. Cancer Res., May 1, 2003; 9(5): 1885 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yao, S. Kargman, E. C. Lam, C. R. Kelly, Y. Zheng, P. Luk, E. Kwong, J. F. Evans, and M. M. Wolfe Inhibition of Cyclooxygenase-2 by Rofecoxib Attenuates the Growth and Metastatic Potential of Colorectal Carcinoma in Mice Cancer Res., February 1, 2003; 63(3): 586 - 592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Chu, F. L. Lloyd, O. C. Trifan, B. Knapp, and M. T. Rizzo Potential Involvement of the Cyclooxygenase-2 Pathway in the Regulation of Tumor-associated Angiogenesis and Growth in Pancreatic Cancer Mol. Cancer Ther., January 1, 2003; 2(1): 1 - 7. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Wali, S. Khare, M. Tretiakova, G. Cohen, L. Nguyen, J. Hart, J. Wang, M. Wen, A. Ramaswamy, L. Joseph, et al. Ursodeoxycholic Acid and F6-D3 Inhibit Aberrant Crypt Proliferation in the Rat Azoxymethane Model of Colon Cancer: Roles of Cyclin D1 and E-Cadherin Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1653 - 1662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. A. Qadri, J. H. Wang, K. C. Redmond, A. F. O'Donnell, T. Aherne, and H. P. Redmond The role of COX-2 inhibitors in lung cancer Ann. Thorac. Surg., November 1, 2002; 74(5): 1648 - 1652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. P. Femia, C. Luceri, P. Dolara, A. Giannini, A. Biggeri, M. Salvadori, Y. Clune, K. J. Collins, M. Paglierani, and G. Caderni Antitumorigenic activity of the prebiotic inulin enriched with oligofructose in combination with the probiotics Lactobacillus rhamnosus and Bifidobacterium lactis on azoxymethane-induced colon carcinogenesis in rats Carcinogenesis, November 1, 2002; 23(11): 1953 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. K. Bol, R. B. Rowley, C.-P. Ho, B. Pilz, J. Dell, M. Swerdel, K. Kiguchi, S. Muga, R. Klein, and S. M. Fischer Cyclooxygenase-2 Overexpression in the Skin of Transgenic Mice Results in Suppression of Tumor Development Cancer Res., May 1, 2002; 62(9): 2516 - 2521. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, C. Indranie, B. Simi, P. T. Manning, J. R. Connor, and B. S. Reddy Chemopreventive Properties of a Selective Inducible Nitric Oxide Synthase Inhibitor in Colon Carcinogenesis, Administered Alone or in Combination with Celecoxib, a Selective Cyclooxygenase-2 Inhibitor Cancer Res., January 1, 2002; 62(1): 165 - 170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. B. Mills Mechanisms Underlying Chemoprevention of Ovarian Cancer Clin. Cancer Res., January 1, 2002; 8(1): 7 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Rodriguez-Burford, M. N. Barnes, D. K. Oelschlager, R. B. Myers, L. I. Talley, E. E. Partridge, and W. E. Grizzle Effects of Nonsteroidal Anti-Inflammatory Agents (NSAIDs) on Ovarian Carcinoma Cell Lines: Preclinical Evaluation of NSAIDs as Chemopreventive Agents Clin. Cancer Res., January 1, 2002; 8(1): 202 - 209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Han, P. Pantazis, J. H. Wyche, N. Kouttab, V. J. Kidd, and E. A. Hendrickson A Fas-associated Death Domain Protein-dependent Mechanism Mediates the Apoptotic Action of Non-steroidal Anti-inflammatory Drugs in the Human Leukemic Jurkat Cell Line J. Biol. Chem., October 12, 2001; 276(42): 38748 - 38754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. TEGEDER, J. PFEILSCHIFTER, and G. GEISSLINGER Cyclooxygenase-independent actions of cyclooxygenase inhibitors FASEB J, October 1, 2001; 15(12): 2057 - 2072. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Kurie and R. N. Dubois Prostaglandin E Synthase: Another Enzyme in the Cyclooxygenase Pathway Driving Epithelial Cancer? Clin. Cancer Res., September 1, 2001; 7(9): 2608 - 2610. [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Gilroy, M. A. Saunders, and K. K. Wu COX-2 expression and cell cycle progression in human fibroblasts Am J Physiol Cell Physiol, July 1, 2001; 281(1): C188 - C194. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Saukkonen, O. Nieminen, B. van Rees, S. Vilkki, M. Harkonen, M. Juhola, J.-P. Mecklin, P. Sipponen, and A. Ristimaki Expression of Cyclooxygenase-2 in Dysplasia of the Stomach and in Intestinal-type Gastric Adenocarcinoma Clin. Cancer Res., July 1, 2001; 7(7): 1923 - 1931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shono, P. J. Tofilon, J. M. Bruner, O. Owolabi, and F. F. Lang Cyclooxygenase-2 Expression in Human Gliomas: Prognostic Significance and Molecular Correlations Cancer Res., June 1, 2001; 61(11): 4375 - 4381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W A Brown, S A Skinner, C Malcontenti-Wilson, D Vogiagis, and P E O'Brien Non-steroidal anti-inflammatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a DMH rodent model by inducing apoptosis and inhibiting cell proliferation Gut, May 1, 2001; 48(5): 660 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Bae, E. S. Jung, Y. M. Park, B. S. Kim, B. K. Kim, D. G. Kim, and W. S. Ryu Expression of Cyclooxygenase-2 (COX-2) in Hepatocellular Carcinoma and Growth Inhibition of Hepatoma Cell Lines by a COX-2 Inhibitor, NS-398 Clin. Cancer Res., May 1, 2001; 7(5): 1410 - 1418. [Abstract] [Full Text]
|
|
|
|
|
|
Z. Li, Y. Shimada, A. Kawabe, F. Sato, M. Maeda, I. Komoto, T. Hong, Y. Ding, J. Kaganoi, and M. Imamura Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor Carcinogenesis, April 1, 2001; 22(4): 547 - 551. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Richter, M. Weiss, I. Weinberger, G. Furstenberger, and B. Marian Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors Carcinogenesis, January 1, 2001; 22(1): 17 - 25. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y Kishimoto, N Takata, T Jinnai, T Morisawa, G Shiota, H Kawasaki, and J Hasegawa Sulindac and a cyclooxygenase-2 inhibitor, etodolac, increase APC mRNA in the colon of rats treated with azoxymethane Gut, December 1, 2000; 47(6): 812 - 819. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F.-L. Chung, C.C. Conaway, C.V. Rao, and B. S. Reddy Chemoprevention of colonic aberrant crypt foci in Fischer rats by sulforaphane and phenethyl isothiocyanate Carcinogenesis, December 1, 2000; 21(12): 2287 - 2291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. F. Souza, K. Shewmake, D. G. Beer, B. Cryer, and S. J. Spechler Selective Inhibition of Cyclooxygenase-2 Suppresses Growth and Induces Apoptosis in Human Esophageal Adenocarcinoma Cells Cancer Res., October 1, 2000; 60(20): 5767 - 5772. [Abstract] [Full Text]
|
|
|
|
|
|
P. C. Chulada, M. B. Thompson, J. F. Mahler, C. M. Doyle, B. W. Gaul, C. Lee, H. F. Tiano, S. G. Morham, O. Smithies, and R. Langenbach Genetic Disruption of Ptgs-1, as well as of Ptgs-2, Reduces Intestinal Tumorigenesis in Min Mice Cancer Res., September 1, 2000; 60(17): 4705 - 4708. [Abstract] [Full Text]
|
|
|
|
|
|
R. F. Jacoby, K. Seibert, C. E. Cole, G. Kelloff, and R. A. Lubet The Cyclooxygenase-2 Inhibitor Celecoxib Is a Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis Cancer Res., September 1, 2000; 60(18): 5040 - 5044. [Abstract] [Full Text]
|
|
|
|
|
|
Y. Yamada, N. Yoshimi, Y. Hirose, K. Kawabata, K. Matsunaga, M. Shimizu, A. Hara, and H. Mori Frequent {beta}-Catenin Gene Mutations and Accumulations of the Protein in the Putative Preneoplastic Lesions Lacking Macroscopic Aberrant Crypt Foci Appearance, in Rat Colon Carcinogenesis Cancer Res., July 1, 2000; 60(13): 3323 - 3327. [Abstract] [Full Text]
|
|
|
|
 |
|
 G. Steinbach, P. M. Lynch, R. K.S. Phillips, M. H. Wallace, E. Hawk, G. B. Gordon, N. Wakabayashi, B. Saunders, Y. Shen, T. Fujimura, et al. The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis N. Engl. J. Med., June 29, 2000; 342(26): 1946 - 1952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Shirahama Cyclooxygenase-2 Expression Is Up-Regulated in Transitional Cell Carcinoma and Its Preneoplastic Lesions in the Human Urinary Bladder Clin. Cancer Res., June 1, 2000; 6(6): 2424 - 2430. [Abstract] [Full Text]
|
|
|
|
|
|
D. Tardieu, J.-P. Jaeg, A. Deloly, D. E. Corpet, J. Cadet, and C. R. Petit The COX-2 inhibitor nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates apoptosis in mucosa during early colonic inflammation in rats Carcinogenesis, May 1, 2000; 21(5): 973 - 976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Shamma, H. Yamamoto, Y. Doki, J. Okami, M. Kondo, Y. Fujiwara, M. Yano, M. Inoue, N. Matsuura, H. Shiozaki, et al. Up-Regulation of Cyclooxygenase-2 in Squamous Carcinogenesis of the Esophagus Clin. Cancer Res., April 1, 2000; 6(4): 1229 - 1238. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy Novel Approaches to the Prevention of Colon Cancer by Nutritional Manipulation and Chemoprevention Cancer Epidemiol. Biomarkers Prev., March 1, 2000; 9(3): 239 - 247. [Abstract] [Full Text]
|
|
|
|
|
|
S. P. Bach, A. G. Renehan, and C. S. Potten Stem cells: the intestinal stem cell as a paradigm Carcinogenesis, March 1, 2000; 21(3): 469 - 476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Masferrer, K. M. Leahy, A. T. Koki, B. S. Zweifel, S. L. Settle, B. M. Woerner, D. A. Edwards, A. G. Flickinger, R. J. Moore, and K. Seibert Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors Cancer Res., March 1, 2000; 60(5): 1306 - 1311. [Abstract] [Full Text]
|
|
|
|
|
|
H. Sheng, J. Shao, D. A. Dixon, C. S. Williams, S. M. Prescott, R. N. DuBois, and R. D. Beauchamp Transforming Growth Factor-beta 1 Enhances Ha-ras-induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of mRNA J. Biol. Chem., February 25, 2000; 275(9): 6628 - 6635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tsutsumi, H. Kitada, K. Shiraiwa, M. Takahama, T. Tsujiuchi, H. Sakitani, Y. Sasaki, K. Murakawa, M. Yoshimoto, and Y. Konishi Inhibitory effects of combined administration of antibiotics and anti-inflammatory drugs on lung tumor development initiated by N-nitrosobis(2-hydroxypropyl)amine in rats Carcinogenesis, February 1, 2000; 21(2): 251 - 256. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Y. Lim, H. J. Joo, J. H. Choi, J. W. Yi, M. S. Yang, D. Y. Cho, H. S. Kim, D. K. Nam, K. B. Lee, and H. C. Kim Increased Expression of Cyclooxygenase-2 Protein in Human Gastric Carcinoma Clin. Cancer Res., February 1, 2000; 6(2): 519 - 525. [Abstract] [Full Text]
|
|
|
|
|
|
D. Wolfle, S. Marotzki, D. Dartsch, W. Schafer, and H. Marquardt Induction of cyclooxygenase expression and enhancement of malignant cell transformation by 2,3,7,8-tetrachlorodibenzo- p-dioxin Carcinogenesis, January 1, 2000; 21(1): 15 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, and C. V. Rao Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis Cancer Res., January 1, 2000; 60(2): 293 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
A WATSON and R N DuBOIS Cryptic messages in FAP Gut, December 1, 1999; 45(6): 795 - 796. [Full Text] [PDF]
|
|
|
|
|
|
M. Kondo, H. Yamamoto, H. Nagano, J. Okami, Y. Ito, J. Shimizu, H. Eguchi, A. Miyamoto, K. Dono, K. Umeshita, et al. Increased Expression of COX-2 in Nontumor Liver Tissue Is Associated with Shorter Disease-free Survival in Patients with Hepatocellular Carcinoma Clin. Cancer Res., December 1, 1999; 5(12): 4005 - 4012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Watanabe, T. Kawamori, S. Nakatsugi, T. Ohta, S. Ohuchida, H. Yamamoto, T. Maruyama, K. Kondo, F. Ushikubi, S. Narumiya, et al. Role of the Prostaglandin E Receptor Subtype EP1 in Colon Carcinogenesis Cancer Res., October 1, 1999; 59(20): 5093 - 5096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Okami, H. Yamamoto, Y. Fujiwara, M. Tsujie, M. Kondo, S. Noura, S. Oshima, H. Nagano, K. Dono, K. Umeshita, et al. Overexpression of Cyclooxygenase-2 in Carcinoma of the Pancreas Clin. Cancer Res., August 1, 1999; 5(8): 2018 - 2024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Hong, I. Avis, M. D. Vos, A. Martinez, A. M. Treston, and J. L. Mulshine Relationship of Arachidonic Acid Metabolizing Enzyme Expression in Epithelial Cancer Cell Lines to the Growth Effect of Selective Biochemical Inhibitors Cancer Res., May 1, 1999; 59(9): 2223 - 2228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Achiwa, Y. Yatabe, T. Hida, T. Kuroishi, K.-i. Kozaki, S. Nakamura, M. Ogawa, T. Sugiura, T. Mitsudomi, and T. Takahashir Prognostic Significance of Elevated Cyclooxygenase 2 Expression in Primary, Resected Lung Adenocarcinomas Clin. Cancer Res., May 1, 1999; 5(5): 1001 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. V. Rao, T. Kawamori, R. Hamid, and B. S. Reddy Chemoprevention of colonic aberrant crypt foci by an inducible nitric oxide synthase-selective inhibitor Carcinogenesis, April 1, 1999; 20(4): 641 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Ritland, J. A. Leighton, R. E. Hirsch, J. D. Morrow, A. L. Weaver, and S. J. Gendler Evaluation of 5-Aminosalicylic Acid (5-ASA) for Cancer Chemoprevention: Lack of Efficacy against Nascent Adenomatous Polyps in the ApcMin Mouse Clin. Cancer Res., April 1, 1999; 5(4): 855 - 863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Shao, H. Sheng, R. Aramandla, M. A. Pereira, R. A. Lubet, E. Hawk, L. Grogan, I. R. Kirsch, M. K. Washington, R. D. Beauchamp, et al. Coordinate regulation of cyclooxygenase-2 and TGF-ß1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors Carcinogenesis, February 1, 1999; 20(2): 185 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Ritland and S. J. Gendler Chemoprevention of intestinal adenomas in the ApcMin mouse by piroxicam: kinetics, strain effects and resistance to chemosuppression Carcinogenesis, January 1, 1999; 20(1): 51 - 58. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C. Zimmermann, M. Sarbia, A.-A. Weber, F. Borchard, H. E. Gabbert, and K. Schror Cyclooxygenase-2 Expression in Human Esophageal Carcinoma Cancer Res., January 1, 1999; 59(1): 198 - 204. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
